RSRC2 | bioCADDIE Data Discovery Index
Mountain View
biomedical and healthCAre Data Discovery Index Ecosystem
help Advanced Search
Displaying 20 of 20 results for "RSRC2"
i
  1. RSRC2_RAT UniProt:Swiss-Prot

    ID: Q5PQR4

    Description: Arginine/serine-rich coiled-coil protein 2

  2. RSRC2_XENTR UniProt:Swiss-Prot

    ID: Q5XHJ5

    Description: Arginine/serine-rich coiled-coil protein 2

  3. RSRC2_MOUSE UniProt:Swiss-Prot

    ID: A2RTL5

    Description: Arginine/serine-rich coiled-coil protein 2

  4. RSRC2_PONAB UniProt:Swiss-Prot

    ID: Q5R8J6

    Description: Removed Arginine/serine-rich coiled-coil protein 2

  5. RSRC2_XENLA UniProt:Swiss-Prot

    ID: Q7ZYR8

    Description: Arginine/serine-rich coiled-coil protein 2

  6. RSRC2_DANRE UniProt:Swiss-Prot

    ID: Q6NWI1

    Description: Arginine/serine-rich coiled-coil protein 2

  7. CLASR_RAT UniProt:Swiss-Prot

    ID: Q5HZB6

    Description: CLK4-associating serine/arginine rich protein Arg-rich Ser-rich Phosphos...

  8. Crystal Structure of Leucine-rich repeat- and Coiled coil-containing Protein from Legionella pneumophila PDB

    ID: PDB:4Q62

    Description: Leucine-rich repeat-and coiled coil-containing protein

  9. aCGH of neuroblastic tumors ArrayExpress

    ID: E-GEOD-18143

    Description: q24.31 amplicon in neuroblastoma (DIABLO, ZCCHC8, RSRC2, KNTC1 and MPHOSPH9). Among these, DIABLO showed the strongest activation suggesting a putative role in neuroblastoma progression. Conclusions: The presented systematic and rapid framework, which integrates aCGH, gene expression and tissue data to obtain novel targets and biomarkers for cancer, identified a low-level gain of the 12q24.31 as a potential new biomarker for neuroblastoma progression. Furthermore, results of in silico data mining suggest a new neuroblastoma target gene, DIABLO, within this region, whose functional and therapeutic role remains to be elucidated in follow-up studies. High-resolution aCGH was utilized to identify novel genetic alterations in two neuroblastoma cell lines, NGP and IMR-32. Through the integration of gene copy number and gene expression data, the impact of copy number changes on expression levels was determined. Fluorescence in situ hybridization (FISH) on a tissue microarray (TMA) format was used to assess the clinical significance of the identified copy number increase at 12q24.31 in neuroblastoma patients. Finally, we used in silico data mining of publicly available transcriptomics data, to evaluate the transcriptional consequences of the detected 12q24.31 alteration and to identify subsequently activated gene(s). Here, aCGH of the NGP and IMR-32 cell lines was performed. Male genomic DNA was used as reference....

  10. Array-based gene expression in neuroblastic tumors ArrayExpress

    ID: E-GEOD-18139

    Description: q24.31 amplicon in neuroblastoma (DIABLO, ZCCHC8, RSRC2, KNTC1 and MPHOSPH9). Among these, DIABLO showed the strongest activation suggesting a putative role in neuroblastoma progression. Conclusions: The presented systematic and rapid framework, which integrates aCGH, gene expression and tissue data to obtain novel targets and biomarkers for cancer, identified a low-level gain of the 12q24.31 as a potential new biomarker for neuroblastoma progression. Furthermore, results of in silico data mining suggest a new neuroblastoma target gene, DIABLO, within this region, whose functional and therapeutic role remains to be elucidated in follow-up studies. High-resolution aCGH was utilized to identify novel genetic alterations in two neuroblastoma cell lines, NGP and IMR-32. Through the integration of gene copy number and gene expression data, the impact of copy number changes on expression levels was determined. Fluorescence in situ hybridization (FISH) on a tissue microarray (TMA) format was used to assess the clinical significance of the identified copy number increase at 12q24.31 in neuroblastoma patients. Finally, we used in silico data mining of publicly available transcriptomics data, to evaluate the transcriptional consequences of the detected 12q24.31 alteration and to identify subsequently activated gene(s). Here, gene expression analysis of the NGP and IMR-32 cell lines was performed. A pooled sample of 16 cancer cell lines was used as reference....

  11. HUMAN SPLICING FACTOR, CONSTRUCT 3 PDB

    ID: PDB:4WII

    Description: SPLICING FACTOR, PROLINE- AND GLUTAMINE-RICH

  12. HUMAN SPLICING FACTOR, CONSTRUCT 2 PDB

    ID: PDB:4WIK

    Description: SPLICING FACTOR, PROLINE- AND GLUTAMINE-RICH

  13. Discovery of Non-ETS Gene Fusions using RNA Sequencing dbGaP

    ID: phs000310.v1.p1

    Description: s the oncogene PIGU and the tumor suppressor gene RSRC2. The novel gene fusions are found to be of low frequency but interestingly, the non-ETS fusions were all present in prostate cancer harboring the TMPRSS2-ERG gene fusion. Future work will focus on determining if the ETS rearrangements in prostate cancer are associated or directly predispose to a rearrangement prone phenotype....

    Study Types: Cohort

  14. Discovery of Non-ETS Gene Fusions in Human Prostate Cancer using Next Generation RNA Sequencing OmicsDI

    ID: phs000310.v1.p1

    Date Released:

    Description: he oncogene PIGU and the tumor suppressor gene RSRC2. The novel gene fusions are found to be of low frequency but interestingly, the non-ETS fusions were all present in prostate cancer harboring the TMPRSS2-ERG gene fusion. Future work will focus on determining if the ETS rearrangements in prostate cancer are associated or directly predispose to a rearrangement prone phenotype.

    ...

  15. Array-based gene expression in neuroblastic tumors BioProject

    ID: PRJNA123479

    Keywords: Transcriptome or Gene expression

    Access Type: download

    dataset.description: q24.31 amplicon in neuroblastoma (DIABLO, ZCCHC8, RSRC2, KNTC1 and MPHOSPH9). Among these, DIABLO showed the strongest activation suggesting a putative role in neuroblastoma progression. Conclusions: The presented systematic and rapid framework, which integrates aCGH, gene expression and tissue data to obtain novel targets and biomarkers for cancer, identified a low-level gain of the 12q24.31 as a potential new biomarker for neuroblastoma progression. Furthermore, results of in silico data mining suggest a new neuroblastoma target gene, DIABLO, within this region, whose functional and therapeutic role remains to be elucidated in follow-up studies. Overall design: High-resolution aCGH was utilized to identify novel genetic alterations in two neuroblastoma cell lines, NGP and IMR-32. Through the integration of gene copy number and gene expression data, the impact of copy number changes on expression levels was determined. Fluorescence in situ hybridization (FISH) on a tissue microarray (TMA) format was used to assess the clinical significance of the identified copy number increase at 12q24.31 in neuroblastoma patients. Finally, we used in silico data mining of publicly available transcriptomics data, to evaluate the transcriptional consequences of the detected 12q24.31 alteration and to identify subsequently activated gene(s). Here, gene expression analysis of the NGP and IMR-32 cell lines was performed. A pooled sample of 16 cancer cell lines was used as reference....
  16. aCGH of neuroblastic tumors BioProject

    ID: PRJNA123483

    Keywords: Variation

    Access Type: download

    dataset.description: q24.31 amplicon in neuroblastoma (DIABLO, ZCCHC8, RSRC2, KNTC1 and MPHOSPH9). Among these, DIABLO showed the strongest activation suggesting a putative role in neuroblastoma progression. Conclusions: The presented systematic and rapid framework, which integrates aCGH, gene expression and tissue data to obtain novel targets and biomarkers for cancer, identified a low-level gain of the 12q24.31 as a potential new biomarker for neuroblastoma progression. Furthermore, results of in silico data mining suggest a new neuroblastoma target gene, DIABLO, within this region, whose functional and therapeutic role remains to be elucidated in follow-up studies. Overall design: High-resolution aCGH was utilized to identify novel genetic alterations in two neuroblastoma cell lines, NGP and IMR-32. Through the integration of gene copy number and gene expression data, the impact of copy number changes on expression levels was determined. Fluorescence in situ hybridization (FISH) on a tissue microarray (TMA) format was used to assess the clinical significance of the identified copy number increase at 12q24.31 in neuroblastoma patients. Finally, we used in silico data mining of publicly available transcriptomics data, to evaluate the transcriptional consequences of the detected 12q24.31 alteration and to identify subsequently activated gene(s). Here, aCGH of the NGP and IMR-32 cell lines was performed. Male genomic DNA was used as reference....
  17. Discovery of Non-ETS Gene Fusions in Human Prostate Cancer using Next Generation RNA Sequencing BioProject

    ID: PRJNA74905

    Access Type: download

    dataset.description: s the oncogene PIGU and the tumor suppressor gene RSRC2... (for more see dbGaP study page.)...
  18. Discovery of Non-ETS Gene Fusions in Human Prostate Cancer using Next Generation RNA Sequencing BioProject

    ID: PRJNA74907

    Keywords: Phenotype or Genotype

    Access Type: download

    dataset.description: s the oncogene PIGU and the tumor suppressor gene RSRC2... (for more see dbGaP study page.)...
  19. Array-based gene expression in neuroblastic tumors OmicsDI

    ID: E-GEOD-18139

    Date Released: 05-02-2014

    Description: q24.31 amplicon in neuroblastoma (DIABLO, ZCCHC8, RSRC2, KNTC1 and MPHOSPH9). Among these, DIABLO showed the strongest activation suggesting a putative role in neuroblastoma progression. Conclusions: The presented systematic and rapid framework, which integrates aCGH, gene expression and tissue data to obtain novel targets and biomarkers for cancer, identified a low-level gain of the 12q24.31 as a potential new biomarker for neuroblastoma progression. Furthermore, results of in silico data mining suggest a new neuroblastoma target gene, DIABLO, within this region, whose functional and therapeutic role remains to be elucidated in follow-up studies. High-resolution aCGH was utilized to identify novel genetic alterations in two neuroblastoma cell lines, NGP and IMR-32. Through the integration of gene copy number and gene expression data, the impact of copy number changes on expression levels was determined. Fluorescence in situ hybridization (FISH) on a tissue microarray (TMA) format was used to assess the clinical significance of the identified copy number increase at 12q24.31 in neuroblastoma patients. Finally, we used in silico data mining of publicly available transcriptomics data, to evaluate the transcriptional consequences of the detected 12q24.31 alteration and to identify subsequently activated gene(s). Here, gene expression analysis of the NGP and IMR-32 cell lines was performed. A pooled sample of 16 cancer cell lines was used as reference....

  20. aCGH of neuroblastic tumors OmicsDI

    ID: E-GEOD-18143

    Date Released: 05-02-2014

    Description: q24.31 amplicon in neuroblastoma (DIABLO, ZCCHC8, RSRC2, KNTC1 and MPHOSPH9). Among these, DIABLO showed the strongest activation suggesting a putative role in neuroblastoma progression. Conclusions: The presented systematic and rapid framework, which integrates aCGH, gene expression and tissue data to obtain novel targets and biomarkers for cancer, identified a low-level gain of the 12q24.31 as a potential new biomarker for neuroblastoma progression. Furthermore, results of in silico data mining suggest a new neuroblastoma target gene, DIABLO, within this region, whose functional and therapeutic role remains to be elucidated in follow-up studies. High-resolution aCGH was utilized to identify novel genetic alterations in two neuroblastoma cell lines, NGP and IMR-32. Through the integration of gene copy number and gene expression data, the impact of copy number changes on expression levels was determined. Fluorescence in situ hybridization (FISH) on a tissue microarray (TMA) format was used to assess the clinical significance of the identified copy number increase at 12q24.31 in neuroblastoma patients. Finally, we used in silico data mining of publicly available transcriptomics data, to evaluate the transcriptional consequences of the detected 12q24.31 alteration and to identify subsequently activated gene(s). Here, aCGH of the NGP and IMR-32 cell lines was performed. Male genomic DNA was used as reference....


Displaying 20 of 20 results for "RSRC2"